Novartis Research and Development.
ICONIC, Galapagos, JANSSEN, Novartis
May 2023 - Current (3 years 6 months)
A phase 2, multicenter, multinational, randomized, double-blind, placebo controlled study to assess the safety, efficacy, and pharmacokinetics of multiple dose levels of ESK-001 in adult patients with systemic lupus erythematosus. 77242113PSO3001 A Phase 3 multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of participants with moderate to severe plaque psoriasis with randomized withdrawal and retreatment. (VAY736). Clinical Trial Protocol A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in participants with active lupus ne